<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01279798</url>
  </required_header>
  <id_info>
    <org_study_id>NR001-04</org_study_id>
    <nct_id>NCT01279798</nct_id>
  </id_info>
  <brief_title>Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)</brief_title>
  <official_title>Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovaRx Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovaRx Corporation</source>
  <brief_summary>
    <textblock>
      This is an expanded access protocol designed to make Lucanix® available to subjects with&#xD;
      advanced non-small cell lung cancer (NSCLC) who are not eligible for the Phase III Protocol,&#xD;
      NR001-03. A total of 45 patients will be enrolled into the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to increase the overall survival of the study subjects&#xD;
      by providing expanded access to Lucanix. Overall survival and progression-free survivals will&#xD;
      be compared with historical controls.&#xD;
&#xD;
      The secondary objectives of this study are:&#xD;
&#xD;
        -  Evaluate the best overall tumor response.&#xD;
&#xD;
        -  Evaluate progression-free survival (PFS).&#xD;
&#xD;
        -  Evaluate treatment toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Non-small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lucanix® (belagenpumatucel-L)</intervention_name>
    <description>Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.</description>
    <other_name>Lucanix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  Histological confirmed non-curable stage III or IV NSCLC.&#xD;
&#xD;
          -  Must have completed at least one (1) regimen of anti-cancer therapy.&#xD;
&#xD;
          -  Following frontline therapy, subjects must observe the following wash- out periods:&#xD;
&#xD;
               -  Subjects with stable disease or better must have received the last anti-cancer&#xD;
                  therapy not less than five months prior to enrollment.&#xD;
&#xD;
               -  Subjects with progressive disease must have received the last anti-cancer therapy&#xD;
                  at least one (1) month prior to enrollment.&#xD;
&#xD;
          -  All subjects who have received two (2) or more regimens of therapy must have received&#xD;
             the last anti-cancer therapy at least one (1) month prior to enrollment.&#xD;
&#xD;
          -  Performance status (ECOG) ≤ 2&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm3&#xD;
&#xD;
          -  Total Bilirubin ≤ 2× Upper Limit of Normal&#xD;
&#xD;
          -  AST and ALT ≤ 2× Upper Limit of Normal&#xD;
&#xD;
          -  Creatinine ≤ 2× Upper Limit of Normal&#xD;
&#xD;
          -  Negative pregnancy test for women of childbearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent systemic steroids &gt; 2 mg prednisone/day&#xD;
&#xD;
          -  Prior splenectomy&#xD;
&#xD;
          -  Any chemotherapy, steroid therapy, or investigational anti-cancer agent within 4 weeks&#xD;
             of study entry.&#xD;
&#xD;
          -  Subjects who received prior monotherapy with Lucanix.&#xD;
&#xD;
          -  Symptomatic brain metastases unless treated and stable for ≥ 2 months&#xD;
&#xD;
          -  Known HIV positivity&#xD;
&#xD;
          -  Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled&#xD;
             bacterial, viral, or fungal infections), or other conditions which, in the opinion of&#xD;
             the investigator would compromise protocol objectives.&#xD;
&#xD;
          -  Prior malignancy (excluding non-melanoma carcinomas of the skin) unless in remission&#xD;
             for ≥ 2 years&#xD;
&#xD;
          -  History of psychiatric disorder that would impede adherence to protocol&#xD;
&#xD;
          -  Pregnant or nursing women or refusal to practice contraception if of reproductive&#xD;
             potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Innovative Research Center of California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.novarx.com/</url>
    <description>NovaRx Website</description>
  </link>
  <results_reference>
    <citation>Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006 Oct 10;24(29):4721-30. Epub 2006 Sep 11.</citation>
    <PMID>16966690</PMID>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>October 29, 2010</study_first_submitted>
  <study_first_submitted_qc>January 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2011</study_first_posted>
  <last_update_submitted>February 25, 2011</last_update_submitted>
  <last_update_submitted_qc>February 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Habib Fakhrai, PhD, Chief Scientific Officer and Executive Vice Chairman of the Board</name_title>
    <organization>NovaRx Corporation</organization>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>stage III or IV NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

